Reyvow (Lasmiditan Succinate) Patent Expiration, LOE Window & CMS Spending
Reyvow (Lasmiditan Succinate) by Eli Lilly: FDA Orange Book core substance LOE 2037-12-05 (last listed 2040-07-06), 0 AB generics, $14.3M 2024 CMS Part D & Medicaid spend.
| Regulatory & Reimbursement Dimension | Verified Value |
|---|---|
| Consolidated Sponsor | Eli Lilly |
| FDA Application & Pathway | N211280 (NDA) |
| Exclusivity / Cliff Horizon | Long-Dated Protection (2036+) |
| Core Active-Ingredient LOE Date | 2037-12-05 |
| Last Listed Patent or Exclusivity Date | 2040-07-06 |
| Orange Book Patents (*PED Extensions) | 4 patents (0 *PED) |
| Active AB-Rated Generic Competitors | 0 |
| 2024 CMS Total Public Spend | $14.3M |
| 2024 Medicare Part D Spend | $9.8M |
| 2024 Medicaid Spend | $4.5M |
| Reported Wholesale Price Change (CA SB 17) | 0 statutory filings in 2023 to 2026 panel |
Related Filings Across Meru Platforms
Verified cross-ledger federal filings for Eli Lilly and Company across sibling Meru public-data platforms.